Table 3.
Clinical characteristics based on sFLC ratio values.
| Characteristics | Normal sFLC Ratio |
Abnormal sFLC Ratio |
p Value |
|---|---|---|---|
| n = 5 | n = 29 | ||
| Median age, years (range) | 57 (52–65) | 62 (39–73) | 0.8121 |
| M/F | 2/3 | 16/13 | 0.6481 |
| ECOG Performance Status | 0.3894 | ||
| 0–1 | 4 | 27 | |
| 2 | 1 | 2 | |
| Presence of comorbidities | 1/5 | 17/29 | 0.1642 |
| M-protein type | 0.6253 | ||
| IgG/Others | 4/1 | 16/13 | |
| Type of free light chains | >0.9999 | ||
| κ/λ | 2/3 | 15/14 | |
| R-ISS stage | 0.3086 | ||
| 1–2 | 5 | 21 | |
| 3 | 0 | 8 | |
| Cytogenetic abnormalities | 0.2500 | ||
| Normal/others | 3/0 | 12/10 | |
| Not performed | 2 | 7 | |
| Presence of del(17p)/absence of del(17p) | 0/3 | 4/22 | >0.9999 |
| Not performed | 2 | 3 | |
| Median M-protein, g/dL (range) | 3.12 (2.75–5.23) | 1.89 (0–5.9) | 0.1024 |
| Median involved chain, mg/L (range) | 9.8 (7.9–14.9) | 163 (15.6–19, 300) | 0.3684 |
| Median uninvolved chain, mg/L (range) | 8 (6.1–10.9) | 9.4 (1.8–54.6) | 0.4170 |
| Median FLC ratio | 1.3 (1–1.5) | 18.5 (2.4–3641) | 0.4598 |
| Presence of urinary Bence Jones protein | 1/5 | 19/29 | 0.1349 |
| Median β2-microglobulin, mg/dL (range) | 3.3 (2.92–3.8) | 3.3 (1.4–19) | 0.9874 |
| Abnormal/normal β2-microglobulin | 5/0 | 23/6 | 0.5585 |
| Median LDH, U/L (range) | 402 (364–901) | 394 (217–755) | 0.1959 |
| Median albumin, g/dL (range) | 2.9 (2.7–3.8) | 3.4 (2–4.9) | 0.2878 |
| Median GFR, mL/min (range) | 112 (55–115) | 90 (4–123) | 0.2214 |
| Abnormal GFR | 1/5 | 7/29 | >0.9999 |
| Presence of renal failure | 1/5 | 8/29 | >0.9999 |
| Presence of osteolytic lesions | 3/5 | 17/29 | 0.6343 |
| More than 2 osteolytic lesions | 1/5 | 13/29 | >0.9999 |
| Presence of hypercalcemia | 1/5 | 2/29 | 0.3894 |
| Presence of anemia | 3/5 | 20/29 | >0.9999 |
| Pre-HSCT renal failure | 1/5 | 7/29 | >0.9999 |
| Pre-HSCT status | >0.9999 >0.9999 |
||
| CR | 4 | 19 | |
| SD/PR | 1 | 10 | |
| Auto-HSCT | |||
| Single/tandem | 4/1 | 24/5 | |
| Maintenance treatment | 2/5 | 17/29 | 0.6343 |
| Relapse | 2/5 | 5/29 | 0.2684 |
| Best response | 0.1317 | ||
| SD | 0 | 2 | |
| PR | 0 | 2 | |
| VgPR | 0 | 9 | |
| CR/sCR | 5 | 16 | |
| Deaths | 1/5 | 8/29 | >0.9999 |
| Median OS, months (range) | 68.9 (23.9–73.9) | 41.9 (10.4–103.9) | 0.8415 |
| Median PFS, months (range) | 67 (20–73.9) | 40.6 (6.9–103.9) | 0.7238 |
Abbreviations. Ig, immunoglobulin; R-ISS, revised international staging system; BM, bone marrow; FLC, free light chain; LDH, lactate dehydrogenase; eGFR, estimated glomerular filtration rate; PAD, bortezomib, dexamethasone, and doxorubicin; VD, bortezomib and dexamethasone; VRD, bortezomib, lenalidomide, and dexamethasone; VTD, bortezomib, thalidomide, and dexamethasone; HSCT, hematopoietic stem cell transplantation; auto-HSCT, autologous HSCT; RD, lenalidomide and dexamethasone; SD, stable disease; PR, partial remission; VgPR, very good partial remission; CR, complete remission; sCR, stringent CR.